320 related articles for article (PubMed ID: 22370799)
1. [Off-label therapy in rheumatology].
Krüger K; Sieper J
Z Rheumatol; 2012 Feb; 71(2):99-100. PubMed ID: 22370799
[No Abstract] [Full Text] [Related]
2. [Solutions for off-label therapy].
Schmidt WA
Z Rheumatol; 2003; 62(Suppl 2):II54-6. PubMed ID: 14648094
[TBL] [Abstract][Full Text] [Related]
3. [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].
Janzen RW; Ludwig WD;
Z Rheumatol; 2012 Feb; 71(2):108-10, 112-8. PubMed ID: 22370801
[TBL] [Abstract][Full Text] [Related]
4. [Off-label therapy from the perspective of the medical insurance service].
Grell L; Rieger M
Z Rheumatol; 2012 Feb; 71(2):101-4, 106-7. PubMed ID: 22370800
[TBL] [Abstract][Full Text] [Related]
5. [Off-label therapy of rheumatoid arthritis and spondyloarthritis].
Krüger K; Sieper J
Z Rheumatol; 2012 Feb; 71(2):122-4, 126. PubMed ID: 22370803
[TBL] [Abstract][Full Text] [Related]
6. [Limited prescribing freedom by federal cost regulation?].
Lasek R
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):633-5. PubMed ID: 9527458
[TBL] [Abstract][Full Text] [Related]
7. [Leflunomide and TNF inhibitors. Experiences from precription recourse proceedings].
Brandt-Jürgens J
Z Rheumatol; 2013 Mar; 72(2):114-6. PubMed ID: 23223912
[No Abstract] [Full Text] [Related]
8. [How AMOG limits the supply of diabetes drugs].
Oberhofer E
MMW Fortschr Med; 2015 Aug; 157(14):24. PubMed ID: 26289868
[No Abstract] [Full Text] [Related]
9. [Medication prices in Germany--how are they determined?].
Bruhn C
Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
[No Abstract] [Full Text] [Related]
10. [Health services research: essential for allocation decisions - joint statement].
Pfaff H; Abholz H; Glaeske G; Icks A; Klinkhammer-Schalke M; Nellessen-Martens G; Neugebauer EA; Ohmann C; Schrappe M; Selbmann HK; Stemmer R;
Dtsch Med Wochenschr; 2011 Dec; 136(48):2496-500. PubMed ID: 21993809
[No Abstract] [Full Text] [Related]
11. [Reimbursement for medical services in rehabilitation. A contribution to uniform measures].
Vömel U
Rehabilitation (Stuttg); 1997 Aug; 36(3):148-51. PubMed ID: 9411625
[No Abstract] [Full Text] [Related]
12. [The costs of new drugs compared to current standard treatment].
Ujeyl M; Schlegel C; Gundert-Remy U
Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):461-7. PubMed ID: 24238023
[TBL] [Abstract][Full Text] [Related]
13. [Legal dispute about the black drug list. Irrespective of positive or negative list--I am in favor].
Thöns M
MMW Fortschr Med; 2006 Oct; 148(40):8. PubMed ID: 17338085
[No Abstract] [Full Text] [Related]
14. Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis.
Seidenschnur KEK; Dressler C; Weller K; Nast A; Werner RN
J Dtsch Dermatol Ges; 2017 Nov; 15(11):1103-1109. PubMed ID: 29064628
[TBL] [Abstract][Full Text] [Related]
15. [The physician caught between two chairs. Comments on the difficulty in dealing with off-label use].
Harder Yv
Urologe A; 2007 Oct; 46(10):1429-34. PubMed ID: 17786403
[No Abstract] [Full Text] [Related]
16. Off-label use reimbursement.
Cohen J; Wilson A; Faden L
Food Drug Law J; 2009; 64(2):391-403. PubMed ID: 19999289
[TBL] [Abstract][Full Text] [Related]
17. [Regresses for medicine prescription: benchmark evaluations should be eliminated].
Dryden WA
MMW Fortschr Med; 2013 Nov; 155 Spec No 2():16. PubMed ID: 24734441
[No Abstract] [Full Text] [Related]
18. [Can physicians really save still more in drug prescriptions?].
Schmidt K
MMW Fortschr Med; 2006 Feb; 148(5):44-5. PubMed ID: 16518938
[No Abstract] [Full Text] [Related]
19. [Off-label use of drugs--the legal framework].
Koyuncu A
Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
[No Abstract] [Full Text] [Related]
20. [Biosimilars - Potential, risks and open questions].
Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
[No Abstract] [Full Text] [Related]
[Next] [New Search]
